Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS

Retrieved on: 2024-01-21 21:53:36

Tags for this article:

Pacific Biosciences

Cantor Fitzgerald

Avita Medical

AxoGen

Revenue

PACIFIC BIOSCIENCES OF CALIFORNIA

Click the tags to see associated articles and topics

Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS. View article details on hiswai:

Summary

The article discusses Cantor Fitzgerald's bullish stance on various MedTech companies, highlighting AVITA Medical for its high growth and margins and Pacific Biosciences for its long-read sequencing capabilities. The related tags focus on these companies' performance and potential in the medical technology market.

Article found on: seekingalpha.com

View Original Article